MedTrace Logo

Amiloride Hydrochloride as an Effective Treatment for ADHD

NCT01733680 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2018-07-20

Study results available
· View outcomes & findings →

Summary

The investigators are proposing to test a medication derived from our prior studies of the gene SLC9A9. This one gene makes NHE proteins that control how we learn and remember items, which is impaired in ADHD and may cause an inability to plan, prioritize, self-monitor,inhibit, initiate, self-correct, or control one's behavior. The investigators now propose to investigate the therapeutic utility of an NHE inhibitor, amiloride hydrochloride, for the treatment of attention deficit hyperactivity disorder (ADHD) in medication-naïve adults with ADHD.

Conditions

  • ADHD

Interventions

DRUG

amiloride

Subjects will take either amiloride hydrochloride or placebo for 8 weeks.

BEHAVIORAL

Behavioral

Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement

Sponsors & Collaborators

  • State University of New York - Upstate Medical University

    lead OTHER

Principal Investigators

  • Stephen V Faraone, PhD · SUNY Upstate Medical Unversity

  • Prashant Kaul, MD · VA Medical Center at Syracuse

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01733680 on ClinicalTrials.gov